Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!
you are here: HomeNewsWorld

'How coronavirus enters cells decoded, may help develop new drugs'

According to the researchers, including those from Icahn School of Medicine at Mount Sinai in the US, understanding how the novel coronavirus, SARS-CoV-2, enters cells, and comparing it to other coronaviruses, is key to identifying treatments against COVID-19.

May 28, 2020 / 01:38 PM IST

Scientists have identified features of the novel coronavirus which enable it to efficiently enter cells, while stealthily evading surveillance by the host immune system, findings that may lead to novel drug targets against COVID-19.

According to the researchers, including those from Icahn School of Medicine at Mount Sinai in the US, understanding how the novel coronavirus, SARS-CoV-2, enters cells, and comparing it to other coronaviruses, is key to identifying treatments against COVID-19.

In the new study, published in the journal PNAS, the scientists assessed how SARS-CoV-2, and the closely related SARS-CoV virus behind the 2002-03 pandemic, use the human ACE2 receptor proteins as entry gates into cells.

By conducting lab tests to understand how synthetic versions of the novel coronavirus and SARS-CoV enter cells, the researchers identified key mechanisms by which SARS-CoV-2 evades the host immune system, and enters cells.

They said the spike protein on the surface of SARS-CoV-2 binds to the host cell receptor ACE2 through a portion on its surface called the receptor-binding domain, or RBD.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The RBD, the scientists said, is activated by biological molecules in humans called proteases.

According to the study, the SARS-CoV-2 RBD has higher ACE2 binding affinity than that of the 2002-03 SARS virus, supporting a more efficient cell entry in the new virus.

However, the researchers said the ACE2 binding affinity of the entire SARS-CoV-2 spike is comparable to, or lower than that of SARS-CoV spike.

"Despite the potency of its RBD's binding to hACE2, the entire SARS-CoV-2 spike does not bind to hACE2 any more strongly than SARS-CoV spike does," the scientists wrote in the study.

Based on this observation, they suggested that SARS-CoV-2 RBD, albeit more potent, is less exposed than SARS-CoV RBD.

The hidden RBD in the novel coronavirus, according to the researchers, can evade the host immune system, potentially leading to insufficient immune responses and prolonged recovery time.

The scientists also found that unlike SARS-CoV, cell entry of SARS-CoV-2 is preactivated by a molecule called proprotein convertase furin.

To maintain its high infectivity while keeping its RBD less accessible, the study noted that the novel coronavirus relies on host protease activation.

Host protease activation is a significant determinant of coronavirus infection, and a significant target for host immune surveillance and human intervention strategies, the researchers said.

"The high ACE2 binding affinity of the RBD, furin preactivation of the spike, and hidden RBD in the spike potentially allow SARS-CoV-2 to maintain efficient cell entry while evading immune surveillance," the researchers wrote in the study.

According to the scientists, these features of the novel coronavirus may contribute to the wide spread of COVID-19.

"Successful intervention strategies must target both the potency of SARS-CoV-2 and its evasiveness," they concluded.

Follow our full coverage of the coronavirus pandemic here.
PTI
first published: May 27, 2020 05:53 pm

stay updated

Get Daily News on your Browser
Sections